Replies to post #62774 on Biotech Values

[DewDiligence]

>MNTA – Has M118 been designed to reduce or eliminate the risk of HIT? From what I've read about HIT, there is still a risk of developing HIT from the administration of LMWH, but not as great as with unfractionated heparin.<

As far as I can tell, M118 should have an HIT frequency that is comparable to Lovenox’s. The FDA label for Lovenox states that:

>>
Moderate thrombocytopenia (platelet counts of 50-100K/mm3) occurred at a rate of 1.3% in patients given Lovenox, 1.2% in patients given heparin, and 0.7% in patients given placebo...
<<

However, reversibility with protamine (which can’t be done with Lovenox) ought to put the weighted risk of HIT and other thrombocytopenia pretty far down on the list of concerns about M118, IMO.